EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA Six-Month Results of a Randomized Controlled Trial
EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA Six-Month Results of a Randomized Controlled Trial
复制标题
DOI：
10.1097/iae.0b013e31819a2d61
复制
发表时间：
2009-03-01
影响因子：
3.3
通讯作者：
Li, Chi-Lai
中科院分区：
文献类型：
--
作者：
Lam, Dennis S. C.;Lai, Timothy Y. Y.;Li, Chi-Lai
目的：评价两种不同剂量的贝伐单抗（阿瓦斯汀）玻璃体内注射治疗弥漫性糖尿病黄斑水肿的疗效。方法：52 例糖尿病黄斑水肿患者的 52 只眼睛随机接受三个月玻璃体内注射 1.25 mg 或 2.5 mg 贝伐单抗。对患者进行为期 6 个月的观察，并评估光学相干断层扫描中央凹厚度、logMAR 最佳矫正视力 (BCVA) 和不良事件。 结果：48 名患者的 48 只眼睛完成了 6 个月的随访并进行了分析。在所有随访中，两组均观察到平均中央凹厚度显着减少（P < 0.013）。基线和 6 个月平均 logMAR BCVA 之间有显着改善，1.25 mg 组的平均 logMAR BCVA 从 0.63 改善至 0.52，2.5 mg 组从 0.60 改善至 0.47。两组在任何时间点的 BCVA 均无显着性差异（P > 0.56）。亚组分析显示，玻璃体内注射贝伐单抗似乎对既往未接受过任何糖尿病黄斑水肿治疗的眼睛更有效。结论：三个月一次玻璃体内注射贝伐单抗可显着降低糖尿病黄斑水肿患者中央凹厚度并改善最佳矫正视力。 1.25 mg 和 2.5 mg 似乎具有相似的治疗效果。
Purpose: To evaluate the efficacy of intravitreal injections of two different dosages of bevacizumab (Avastin) for treating diffuse diabetic macular edema.Methods: Fifty-two eyes of 52 patients with diabetic macular edema were randomized to receive three monthly intravitreal injections of 1.25 mg or 2.5 mg bevacizumab. Patients were observed for 6 months and optical coherence tomography central foveal thickness, logMAR best-corrected visual acuity (BCVA), and adverse events were assessed.Results: Forty-eight eyes of 48 patients completed the 6-month follow-up and were analyzed. Significant mean central foveal thickness reductions were observed in both groups at all follow-up visits (P < 0.013). Significant improvements between baseline and 6-month mean logMAR BCVAs were seen, with the mean logMAR BCVA improved from 0.63 to 0.52 in the 1.25 mg group and 0.60 to 0.47 in the 2.5 mg group. No significant difference in BCVA was observed between the two groups at any time point (P > 0.56). Subgroup analysis showed that intravitreal bevacizumab seemed to be more effective in eyes without any previous diabetic macular edema treatment.Conclusions: Three monthly intravitreal bevacizumab injections resulted in significant reduction in central foveal thickness and improvements in BCVA in diabetic macular edema patients. Both 1.25 mg and 2.5 mg seemed to have similar treatment efficacy.